$COR

Campbell Elizabeth S sold $3.7M of COR

Campbell Elizabeth S (Executive Vice President) sold 11,300 shares of Cencora, Inc. (COR) at $324.12 ($3.66M total) on 2026-08-24.

Original reporting
SEC EDGAR · Campbell Elizabeth S
Published Aug 25, 2026, 8:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$COR
Bearish
medium confidence
Mentioned
$COR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORBearishLow
01

Why it matters

The insider sell is material for short‑term traders monitoring insider activity.

02

Market read

Provides fresh insider‑sell data for COR, useful for short‑term positioning.

03

What to watch

No pre‑arranged 10b5‑1 plan; the sale may be driven by personal liquidity needs.

Relevance 6/10Novelty 7/10Timing: post‑market 2026‑08‑24

Background

Form 4 filings disclose insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

$CORBearishMedium confidence
Context

Executive Vice President sold 11,300 shares for $3.66M, reducing her stake to 19,455 shares.

Expected impact

Potential short-term downward pressure on COR stock.

Evidence & confidence

A $3.6M sale by an EVP is material for a mid‑cap stock and is the first public disclosure of the transaction.

Market effects

Minimal impact on the pharmaceutical distribution sector beyond the specific insider activity.

Limited to U.S. markets where COR trades.

Low global relevance; primarily of interest to investors in COR.

Counterpoint

The sale could be a routine portfolio rebalancing rather than a negative signal.

Key entities

  • Campbell Elizabeth S

    Executive Vice President of Cencora, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

HighAI 9/10

Cencora Agrees to Take Controlling Stake in American Oncology Network in $2.4 Billion Deal Spanning 21 States

Cencora agreed to acquire American Oncology Network (AON) for $2.4 billion, expanding its oncology services. The deal, pending approval, includes $2.3 billion at closing plus up to $100 million in contingent value rights. Cencora already owns 4% of AON and aims to increase its stake to 75%. The acquisition is part of a broader trend of drug wholesalers buying cancer practice management companies.

$CORHighAI 9/10

Cencora to buy American Oncology Network in $2.4bn deal

Cencora (COR) agreed to acquire American Oncology Network (AON) for $2.4bn, including $2.3bn at closing and up to $100m in contingent value rights. COR shares fell 4.84% post-announcement, despite recent gains. The deal expands COR's oncology services into 12 new states. COR raised its fiscal 2026 EPS guidance to at least $17.90. The transaction requires regulatory approval and AON stockholder approval.

$CORHighAI 9/10

Cencora, Inc. (COR): Results of Operations and Financial Condition

Cencora, Inc. (COR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CENCORA TO ACQUIRE AMERICAN ONCOLOGY NETWORK TO STRENGTHEN SUPPORT OF COMMUNITY ONCOLOGY Builds on Cencora’s MSO platform by adding complementary capabilities and expanding presence across twelve additional states CONSHOHOCKEN, PA & FORT MYERS, Fla., October 21, 2026

$CORHighAI 9/10

Cencora to acquire American Oncology Network for $2.4 billion

Cencora Inc. (NYSE:COR) will acquire American Oncology Network Inc. (OTCQX:AONC) for $2.4 billion, including $2.3 billion at closing and up to $100 million in contingent value rights. The deal will expand Cencora's oncology services platform. Cencora expects the acquisition to be accretive to earnings per share by the second year post-closing and updated its 2026 EPS guidance to at least $17.90. The transaction is subject to regulatory approvals and AON stockholder approvals.

$CORHighAI 9/10

Cencora, Inc. (COR) to Acquire American Oncology Network for $2.4B EV

Cencora (COR) agreed to acquire American Oncology Network for $2.4B EV, with $2.3B paid at closing and up to $100M in contingent value rights. Cencora expects to pay about $1.7B for 75% ownership if 25% equity is rolled. The deal is expected to be EPS accretive in year two, subject to approvals. According to Cencora, the acquisition aligns with its strategy to expand in oncology services.

HighAI 8/10

Cancer-practice support would expand to 12 more states under Cencora's planned acquisition

Cencora plans to acquire American Oncology Network (AON), expanding its oncology services to 12 more states. The deal aims to enhance care access and support independent practices. Cencora expects the acquisition to be accretive to its adjusted diluted EPS in the second year post-closing. The transaction is subject to regulatory approvals and AON stockholder approvals.